ATE302786T1 - Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv - Google Patents

Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv

Info

Publication number: ATE302786T1
Authority: AT; Austria
Prior art keywords: clarithromycin; polymorph; polymorphes; present; converting
Prior art date: 1999-12-16

Application number

AT00988060T

Other languages

English (en)

Inventor

Ilya Avrutov

Igor Lifshitz

Ronen Borochovitz

Basem Masarwa

Edi Schwartz

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-16

Filing date

2000-12-15

Publication date

2005-09-15

2000-12-15 Application filed by Teva Pharma filed Critical Teva Pharma

2005-09-15 Application granted granted Critical

2005-09-15 Publication of ATE302786T1 publication Critical patent/ATE302786T1/de

Links

AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title abstract 9
229960002626 clarithromycin Drugs 0.000 title abstract 4
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 1
229930006677 Erythromycin A Natural products 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229960003276 erythromycin Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polyamides (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Medicinal Preparation (AREA)

AT00988060T 1999-12-16 2000-12-15 Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv ATE302786T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17122199P	1999-12-16	1999-12-16
US17183999P	1999-12-22	1999-12-22
PCT/US2000/033845 WO2001044262A1 (en)	1999-12-16	2000-12-15	Processes for preparing clarithromycin polymorphs and novel polymorph iv

Publications (1)

Publication Number	Publication Date
ATE302786T1 true ATE302786T1 (de)	2005-09-15

Family

ID=26866853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00988060T ATE302786T1 (de)	1999-12-16	2000-12-15	Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv

Country Status (20)

Country	Link
US (2)	US6599884B2 (de)
EP (1)	EP1254146B1 (de)
JP (1)	JP2003516999A (de)
KR (1)	KR20020070991A (de)
CN (2)	CN1666991A (de)
AT (1)	ATE302786T1 (de)
AU (1)	AU783055B2 (de)
CA (1)	CA2395555A1 (de)
CZ (1)	CZ20021999A3 (de)
DE (1)	DE60022230T2 (de)
ES (1)	ES2244491T3 (de)
HR (1)	HRP20020522A2 (de)
HU (1)	HUP0204091A3 (de)
IL (1)	IL150227A0 (de)
PL (1)	PL364880A1 (de)
PT (1)	PT1254146E (de)
RU (1)	RU2002116232A (de)
SK (1)	SK8322002A3 (de)
WO (1)	WO2001044262A1 (de)
YU (1)	YU45602A (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL356645A1 (en) *	2000-01-11	2004-06-28	Teva Pharmaceutical Industries Ltd.	Processes for preparing clarithromycin polymorphs
US6565882B2 (en)	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
US6544555B2 (en)	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
AU2578701A (en) *	2000-02-29	2001-09-12	Teva Pharma	Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR20030011797A (ko) *	2000-03-28	2003-02-11	바이오케미 게젤샤프트 엠베하	맛이 차폐된 과립형 입자
US6541014B2 (en)	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
US20020068078A1 (en) *	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
EP1648415A4 (de)	2003-07-21	2011-11-16	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
EP1648418A4 (de)	2003-07-21	2011-11-16	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
CA2533292C (en)	2003-07-21	2013-12-31	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
WO2005016311A1 (en)	2003-08-11	2005-02-24	Advancis Pharmaceutical Corporation	Robust pellet
CA2535398C (en)	2003-08-12	2013-11-12	Advancis Pharmaceuticals Corporation	Antibiotic product, use and formulation thereof
EP1658034A4 (de)	2003-08-29	2011-06-22	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
WO2005027877A1 (en)	2003-09-15	2005-03-31	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
WO2005061524A2 (en) *	2003-12-22	2005-07-07	Ranbaxy Laboratories Limited	Process for the preparation of form ii clarithromycin
AU2004308419B2 (en) *	2003-12-24	2011-06-02	Victory Pharma, Inc.	Enhanced absorption of modified release dosage forms
US8715727B2 (en)	2004-07-02	2014-05-06	Shionogi Inc.	Tablet for pulsed delivery
JP2009500356A (ja) *	2005-07-07	2009-01-08	エランファーマインターナショナルリミテッド	ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) *	2005-08-31	2007-04-05	Alembic Limited	Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en)	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
DE102007016367A1 (de)	2007-04-03	2008-10-09	Grünenthal GmbH	Polymorph von Clarithromycin (Form V)
EP2030613A1 (de)	2007-08-17	2009-03-04	Abbott GmbH & Co. KG	Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
US9119769B2 (en)	2011-12-30	2015-09-01	The Curators Of The University Of Missouri	Method for transforming pharmaceutical crystal forms
CN103087130B (zh) *	2013-02-06	2015-12-23	浙江国邦药业有限公司	一种克拉霉素晶型转换方法
EP3578546A1 (de)	2013-11-15	2019-12-11	Akebia Therapeutics Inc.	Feste formen von {[5-(3-chlorophenyl)-3-hydroxypyridin-2-carbonyl]amino}essigsäure, zusammensetzungen und verwendungen davon

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4954572A (de) *	1972-09-29	1974-05-27
FR2473525A1 (fr)	1980-01-11	1981-07-17	Roussel Uclaf	Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en)	1980-06-04	1982-05-25	Taisho Pharmaceutical Co., Ltd.	Novel erythromycin compounds
JPS60214796A (ja)	1984-04-06	1985-10-28	Taisho Pharmaceut Co Ltd	６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja)	1984-10-26	1986-05-22	Taisho Pharmaceut Co Ltd	６−０−メチルエリスロマイシンａ誘導体
US4670549A (en)	1985-03-18	1987-06-02	Taisho Pharmaceutical Co., Ltd.	Method for selective methylation of erythromycin a derivatives
US4660386A (en) *	1985-09-18	1987-04-28	Hansen John C	Diagnostic system for detecting faulty sensors in liquid chiller air conditioning system
US4672056A (en)	1985-11-12	1987-06-09	Abbott Laboratories	Erythromycin A derivatives and method of use
US4640910A (en)	1985-11-12	1987-02-03	Abbott Laboratories	Erythromycin A silylated compounds and method of use
KR960000434B1 (ko)	1986-12-17	1996-01-06	다이쇼 세이야꾸 가부시끼가이샤	에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en)	1987-09-09	1987-10-14	Beecham Group Plc	Chemical compounds
JP2751385B2 (ja)	1988-05-19	1998-05-18	大正製薬株式会社	エリスロマイシンａオキシム及びその塩の製造方法
US5274065A (en) *	1990-10-18	1993-12-28	Technical Development Associates	Polyorganosiloxane-polyamide block copolymers
JPH0665080A (ja) *	1992-03-10	1994-03-08	Godo Shiyusei Kk	α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食
US5872229A (en)	1995-11-21	1999-02-16	Abbott Laboratories	Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en)	1995-11-21	1998-05-26	Abbott Laboratories	6-O-methyl erythromycin D and process for making
US5719272A (en)	1996-04-02	1998-02-17	Abbott Laboratories	2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en)	1996-04-02	1998-11-17	Abbott Laboratories	9-oximesilyl erythromycin a derivatives
US5808017A (en)	1996-04-10	1998-09-15	Abbott Laboratories	Process for preparing erythromycin A oxime
PT915899E (pt)	1996-07-29	2004-11-30	Abbott Lab	Preparacao da forma cristalina ii da eritromicina
US5844105A (en) *	1996-07-29	1998-12-01	Abbott Laboratories	Preparation of crystal form II of clarithromycin
US5858986A (en)	1996-07-29	1999-01-12	Abbott Laboratories	Crystal form I of clarithromycin
US5945405A (en)	1997-01-17	1999-08-31	Abbott Laboratories	Crystal form O of clarithromycin
US5864023A (en)	1997-02-13	1999-01-26	Abbott Laboratories	3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en)	1997-11-17	1998-12-22	Abbott Laboratories	Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en)	1997-12-01	1999-08-03	Abbott Laboratories	Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en)	1997-12-16	1999-04-06	Abbott Laboratories	Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko)	1998-09-09	2003-08-19	한미약품공업 주식회사	잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
AU4942800A (en) *	1999-06-11	2001-01-02	Ranbaxy Laboratories Limited	Novel amorphous form of clarithromycin
PL356645A1 (en) *	2000-01-11	2004-06-28	Teva Pharmaceutical Industries Ltd.	Processes for preparing clarithromycin polymorphs
AU2578701A (en) *	2000-02-29	2001-09-12	Teva Pharma	Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

2000
- 2000-12-15 PT PT00988060T patent/PT1254146E/pt unknown
- 2000-12-15 CN CNA2005100044871A patent/CN1666991A/zh active Pending
- 2000-12-15 ES ES00988060T patent/ES2244491T3/es not_active Expired - Lifetime
- 2000-12-15 EP EP00988060A patent/EP1254146B1/de not_active Expired - Lifetime
- 2000-12-15 IL IL15022700A patent/IL150227A0/xx unknown
- 2000-12-15 AU AU24311/01A patent/AU783055B2/en not_active Ceased
- 2000-12-15 DE DE60022230T patent/DE60022230T2/de not_active Expired - Fee Related
- 2000-12-15 CN CN008189862A patent/CN1217951C/zh not_active Expired - Fee Related
- 2000-12-15 KR KR1020027007611A patent/KR20020070991A/ko not_active Ceased
- 2000-12-15 WO PCT/US2000/033845 patent/WO2001044262A1/en not_active Ceased
- 2000-12-15 CZ CZ20021999A patent/CZ20021999A3/cs unknown
- 2000-12-15 AT AT00988060T patent/ATE302786T1/de not_active IP Right Cessation
- 2000-12-15 HU HU0204091A patent/HUP0204091A3/hu unknown
- 2000-12-15 HR HRP20020522 patent/HRP20020522A2/hr not_active Application Discontinuation
- 2000-12-15 PL PL00364880A patent/PL364880A1/xx unknown
- 2000-12-15 YU YU45602A patent/YU45602A/sh unknown
- 2000-12-15 RU RU2002116232/04A patent/RU2002116232A/ru unknown
- 2000-12-15 JP JP2001544751A patent/JP2003516999A/ja not_active Withdrawn
- 2000-12-15 CA CA002395555A patent/CA2395555A1/en not_active Abandoned
- 2000-12-15 SK SK832-2002A patent/SK8322002A3/sk unknown
- 2000-12-15 US US09/736,449 patent/US6599884B2/en not_active Expired - Fee Related
2003
- 2003-06-10 US US10/459,124 patent/US20040058879A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SK8322002A3 (en)	2003-02-04
US6599884B2 (en)	2003-07-29
AU2431101A (en)	2001-06-25
YU45602A (sh)	2005-06-10
CN1434829A (zh)	2003-08-06
KR20020070991A (ko)	2002-09-11
HUP0204091A3 (en)	2003-05-28
ES2244491T3 (es)	2005-12-16
CN1217951C (zh)	2005-09-07
CZ20021999A3 (cs)	2003-02-12
PL364880A1 (en)	2004-12-27
JP2003516999A (ja)	2003-05-20
EP1254146B1 (de)	2005-08-24
CA2395555A1 (en)	2001-06-21
RU2002116232A (ru)	2004-01-10
HRP20020522A2 (en)	2004-12-31
US20040058879A1 (en)	2004-03-25
AU783055B2 (en)	2005-09-22
HUP0204091A2 (hu)	2003-04-28
DE60022230D1 (de)	2005-09-29
EP1254146A1 (de)	2002-11-06
PT1254146E (pt)	2005-10-31
IL150227A0 (en)	2002-12-01
US20020026038A1 (en)	2002-02-28
EP1254146A4 (de)	2003-04-16
WO2001044262A1 (en)	2001-06-21
CN1666991A (zh)	2005-09-14
DE60022230T2 (de)	2006-01-26

Legal Events

Date	Code	Title	Description
2006-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60022230D1 (de)	2005-09-29	Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
AP1709A (en)	2007-02-27	Ethanolate of azithromycin, process for manufacure, and pharmaceutical compositions thereof.
IL140419A0 (en)	2002-02-10	Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
DE60018119D1 (de)	2005-03-17	Verfahren zur herstellung von polymorphen des clarithromycins
MA27080A1 (fr)	2004-12-20	Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
NZ534374A (en)	2004-12-24	Method of synthesizing camptothecin-relating compounds
CA2295515A1 (en)	1999-02-04	Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
ATE255589T1 (de)	2003-12-15	Kristallin form i von clarithromycin
DE60232158D1 (de)	2009-06-10	Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
DE60119711D1 (de)	2006-06-22	Verfahren zur herstellung von funktionalierten polyalkyleniminen, diese enthaltende zusammenstellungen und ihre verwendungen
ATE386734T1 (de)	2008-03-15	Verfahren zur herstellung von (4-hydroxy-6-oxo- tetrahydropyran-2-yl) acetonitril und dessen derivaten
ATE281434T1 (de)	2004-11-15	Verfahren zur herstellung von benzoperhydroisoindolen
DE60013326D1 (de)	2004-09-30	Verbindungen und verfahren zur behandlung von schmerz
MY120085A (en)	2005-08-30	Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
ATE299851T1 (de)	2005-08-15	Verfahren zur herstellung von zwischenprodukten
NO20031137L (no)	2003-05-05	Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av kiraleforbindelser under betingelsene for en 1,4-Michael-addisjon.Oppfinnelsen angårogså de tilsvarende forbindelser
ATE421961T1 (de)	2009-02-15	Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
ATE259784T1 (de)	2004-03-15	Propanolaminotetraline, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE497498T1 (de)	2011-02-15	Verfahren zur herstellung von oxirancarbonsäuren und derivaten davon
BG104964A (bg)	2001-07-31	Подобрен метод за получаване на фармацевтично ценни норбензоморфанови производни
MXPA04004537A (es)	2004-08-11	Derivados de gabusectina, metodo para produccion de los mismos y uso de los mismos.
MY141464A (en)	2010-04-30	Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
GEP20074181B (en)	2007-08-10	Novel phenylnaphthalene derivatives, method for production thereof and pharmaceutical compositions comprising the same